EndoBionics Inc.
This article was originally published in Start Up
Executive Summary
EndoBionics Inc.'s wire-guided microneedle catheter can traverse the vascular system to inject drugs into deep tissues and major organs, areas that have heretofore been hard to reach in a minimally invasive manner. The company's long-term goal is regenerative medicine, but EndoBionics will seek nearer-term revenues from a first application in coronary restenosis, positioning its MicroSyringe as an alternative to drug-eluting stents.